Metabolic-associated fatty liver disease and lipoprotein metabolism.
Joerg Heeren,Ludger Scheja +1 more
Reads0
Chats0
TLDR
In this article, a review article discusses recent research addressing hepatic lipid synthesis, VLDL production, and lipoprotein internalization as well as the lipid exchange between adipose tissue and the liver in the context of metabolic-associated fatty liver disease.Abstract:
Background Non-alcoholic fatty liver disease, or as recently proposed ‘metabolic-associated fatty liver disease’ (MAFLD), is characterized by pathological accumulation of triglycerides and other lipids in hepatocytes. This common disease can progress from simple steatosis to steatohepatitis, and eventually end-stage liver diseases. MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidemia. Scope of review The liver is the central organ in lipid metabolism by secreting very low density lipoproteins (VLDL) and, on the other hand, by internalizing fatty acids and lipoproteins. This review article discusses recent research addressing hepatic lipid synthesis, VLDL production, and lipoprotein internalization as well as the lipid exchange between adipose tissue and the liver in the context of MAFLD. Major conclusions Liver steatosis in MAFLD is triggered by excessive hepatic triglyceride synthesis utilizing fatty acids derived from white adipose tissue (WAT), de novo lipogenesis (DNL) and endocytosed remnants of triglyceride-rich lipoproteins. In consequence of high hepatic lipid content, VLDL secretion is enhanced, which is the primary cause of complex dyslipidemia typical for subjects with MAFLD. Interventions reducing VLDL secretory capacity attenuate dyslipidemia while they exacerbate MAFLD, indicating that the balance of lipid storage versus secretion in hepatocytes is a critical parameter determining disease outcome. Proof of concept studies have shown that promoting lipid storage and energy combustion in adipose tissues reduces hepatic lipid load and thus ameliorates MAFLD. Moreover, hepatocellular triglyceride synthesis from DNL and WAT-derived fatty acids can be targeted to treat MAFLD. However, more research is needed to understand how individual transporters, enzymes, and their isoforms affect steatosis and dyslipidemia in vivo, and whether these two aspects of MAFLD can be selectively treated. Processing of cholesterol-enriched lipoproteins appears less important for steatosis. It may, however, modulate inflammation and consequently MAFLD progression.read more
Citations
More filters
Journal ArticleDOI
TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
Imke Liebold,Simon F. De Meyer,Markus Heine,Anastasia Kuhl,Jennifer Witt,L. Eissing,Alexander W. Fischer,Anja Christina Koop,Johannes Kluwe,Julian Schulze zur Wiesch,Malte H. Wehmeyer,Uwe Knippschild,Ludger Scheja,Joerg Heeren,Lidia Bosurgi,Anna Worthmann +15 more
TL;DR: In this article , the authors show that TREM2+ macrophages prevent the generation of a pro-inflammatory response elicited by LPS-laden lipoproteins in vitro.
Journal ArticleDOI
Impacts of MicroRNA-483 on Human Diseases
TL;DR: A comprehensive overview of the current understanding regarding the involvement of microRNAs and miR-483-5p in various physiological and pathological processes is provided in this paper , where the authors provide a com-prehensive overview.
Journal ArticleDOI
CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models
Shengjian Huang,Zhou Lin Deng,Wei Eric Wang,Guoqiang Liao,Yiru Zhao,Hua Zhong,Xiang Zhang,Jing Liu,Xuhua Mao,B. Chen,Desi Pan,You Zhou +11 more
TL;DR: In this article , the authors developed a novel oral and liver-targeted THR-β agonist, CS27109, and evaluated its efficacy in the treatment of metabolic disorders.
Journal ArticleDOI
Transcriptomics integrated with metabolomics reveals the ameliorating effect of mussel-derived plasmalogens on high-fat diet-induced hyperlipidemia in zebrafish.
TL;DR: In this article , the metabolic effects of seafood-derived Pls on high fat diet (HFD)-induced hyperlipidemia in zebrafish were evaluated through integrated analyses of hepatic transcriptomics and metabolomics.
Posted ContentDOI
New predictive models and indices for screening MAFLD in school-aged overweight/obese children
TL;DR: Wang et al. as discussed by the authors developed new predictive models and predictors for children with metabolic associated fatty liver disease, which could enhance the feasibility of MAFLD screening programs in the future.
References
More filters
Journal ArticleDOI
A receptor-mediated pathway for cholesterol homeostasis.
TL;DR: The approach was to apply the techniques of cell culture to unravel the postulated regulatory defect in FH, which led to the discovery of a cell surface receptor for a plasma cholesterol transport protein called low density lipoprotein (LDL) and to the elucidation of the mechanism by which this receptor mediates feedback control of cholesterol synthesis.
Journal ArticleDOI
Brown Adipose Tissue: Function and Physiological Significance
Barbara Cannon,Jan Nedergaard +1 more
TL;DR: The development of brown adipose tissue with its characteristic protein, uncoupling protein-1 (UCP1), was probably determinative for the evolutionary success of mammals, as its thermogenesis enhances neonatal survival and allows for active life even in cold surroundings.
Journal ArticleDOI
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L. Donnelly,Coleman Smith,Sarah Jane Schwarzenberg,Jose Jessurun,Mark D. Boldt,Elizabeth J. Parks +5 more
TL;DR: In this article, the authors quantified the biological sources of hepatic and plasma lipoprotein TAG in NAFLD patients, using stable isotopes for four days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipid TAG.
Journal ArticleDOI
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo,Julia Kozlitina,Julia Kozlitina,Chao Xing,Alexander Pertsemlidis,David Cox,Len A. Pennacchio,Len A. Pennacchio,Eric Boerwinkle,Jonathan C. Cohen,Helen H. Hobbs +10 more
TL;DR: Variation in PNPLA3 contributes to ancestry-related and inter-individual differences in hepatic fat content and susceptibility to NAFLD.
Journal ArticleDOI
Mechanisms of NAFLD development and therapeutic strategies
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.
Related Papers (5)
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
Yuki Kawano,David E. Cohen +1 more